gefitinib has been researched along with jnj38877605 in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (jnj38877605) | Trials (jnj38877605) | Recent Studies (post-2010) (jnj38877605) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 27 | 1 | 25 |
| Protein | Taxonomy | gefitinib (IC50) | jnj38877605 (IC50) |
|---|---|---|---|
| Nucleoprotein TPR | Mus musculus (house mouse) | 0.0086 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 0.0042 | |
| Hepatocyte growth factor receptor | Mus musculus (house mouse) | 0.0086 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Damalanka, VC; Janetka, JW; Klampfer, L; Li, S; Mahoney, MW; Primeau, T; Voss, JJLP | 1 |
3 other study(ies) available for gefitinib and jnj38877605
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Discovery; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Macrocyclic Compounds; Mice; Receptor Protein-Tyrosine Kinases; Serine Proteinase Inhibitors; Structure-Activity Relationship | 2021 |